This is a working overview of melanocortin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-29 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The electric charge per mole of elementary charges is a constant called the Faraday constant, F, whose value had been essentially known since 1834 when Michael Faraday published his works on electrolysis. In 1910, Robert Millikan obtained the first measurement of the charge on an electron, −e. The quotient F/e provided an estimate of the Avogadro constant. The classic experiment is that of Bower and Davis at NIST, and relies on dissolving silver metal away from the anode of an electrolysis cell, while passing a constant electric current I for a known time t. If m is the mass of silver lost from the anode and Ar the atomic weight of silver, then the Faraday constant is given by:
=== Pharmacodynamics === EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets. It is a high potency agonist of the serotonin receptors, with its highest binding affinities at the 5-HT1A (Ki = 3.2 nM), 5-HT2B (Ki = 5.3 nM), and 5-HT5A (Ki = 8.6 nM) subtypes. Its 5-HT2A affinity is equivalent to that of LSD, while the affinity to 5-HT2C receptors is 3 times lower than LSD. It shares much of its binding profile with LSD, but does not bind to β1 or β2 adrenergic receptors as LSD does. The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It has about 40% of the potency of LSD in this regard.
Androgens and anabolic steroids like testosterone, dihydrotestosterone (DHT), nandrolone, and oxandrolone, which are full agonists of the androgen receptor, produce virilizing or masculinizing effects like increased sebum production and acne, increased body hair growth, scalp hair loss, voice deepening, increased muscle mass, android fat redistribution, skeletal changes like widening of the shoulders and skull/facial changes, and genital growth both in males and females. SARMs, which are tissue-selective mixed or partial agonists of the androgen receptor, are largely uncharacterized in terms of their masculinizing effects, but are likely to produce many of the same effects. SARMs specifically may be expected to retain masculinizing effects like increased muscle mass and bone changes, while possibly having reduced virilizing effects in certain other areas like androgenic skin and hair changes. Anecdotal reports of masculinization with SARMs in women exist in online forums. The United States Food and Drug Administration (FDA) has cautioned that SARMs could have serious adverse effects ranging from risk of heart attack to stroke and liver damage and has warned against their use in bodybuilding products.
The liquid stationary phase is held in place by gravity or inertia of the molecules composing the stationary phase accelerating toward the center of a centrifuge due to centripetal force. An example of a gravity method is called droplet counter current chromatography (DCCC). There are two modes by which the stationary phase is retained by centripetal force: hydrostatic and hydrodynamic. In the hydrostatic method, the column is rotated about a central axis. Hydrostatic instruments are marketed under the name centrifugal partition chromatography (CPC). Hydrodynamic instruments are often marketed as high-speed or high-performance countercurrent chromatography (HSCCC and HPCCC respectively) instruments which rely on the Archimedes' screw force in a helical coil to retain the stationary phase in the column. The components of a CCC system are similar to most liquid chromatography configurations, such as high-performance liquid chromatography (HPLC). One or more pumps deliver the phases to the column which is the CCC instrument itself. Samples are introduced into the column through a sample loop filled with an automated or manual syringe. The outflow is monitored with various detectors such as ultraviolet–visible spectroscopy or mass spectrometry. The operation of the pumps, CCC instrument, sample injection, and detection may be controlled manually or with a microprocessor.
Sources: en.wikipedia.org
Robinson ran for a third time for Oregon's 4th congressional district in 2014. He was unopposed in the Republican primary and faced another rematch in the general election with DeFazio, who was unopposed in the Democratic primary. Robinson lost the election with 116,534 votes to DeFazio's 181,624.
=== Effects during pregnancy === During human pregnancy, increased fetal production of cortisol between weeks 30 and 32 initiates production of fetal lung pulmonary surfactant to promote maturation of the lungs. In fetal lambs, glucocorticoids (principally cortisol) increase after about day 130, with lung surfactant increasing greatly, in response, by about day 135, and although lamb fetal cortisol is mostly of maternal origin during the first 122 days, 88% or more is of fetal origin by day 136 of gestation. Although the timing of fetal cortisol concentration elevation in sheep may vary somewhat, it averages about 11.8 days before the onset of labor. In several livestock species (e.g. cattle, sheep, goats, and pigs), the surge of fetal cortisol late in gestation triggers the onset of parturition by removing the progesterone block of cervical dilation and myometrial contraction. The mechanisms yielding this effect on progesterone differ among species. In the sheep, where progesterone sufficient for maintaining pregnancy is produced by the placenta after about day 70 of gestation, the prepartum fetal cortisol surge induces placental enzymatic conversion of progesterone to estrogen. (The elevated level of estrogen stimulates prostaglandin secretion and oxytocin receptor development.) Exposure of fetuses to cortisol during gestation can have a variety of developmental outcomes, including alterations in prenatal and postnatal growth patterns.
A gomphosis, also known as a dentoalveolar syndesmosis, or 'peg and socket joint' is a joint that binds the teeth to bony teeth sockets in the maxillary bone and mandible. Gomphos is the Greek word for "bolt". The fibrous connection between a tooth and its socket is a periodontal ligament. Specifically, the connection is made between the maxilla or mandible to the cementum of the tooth. The motion of a gomphosis is minimal, though considerable movement can be achieved over time—the basis of using braces to realign teeth. The joint can be considered a synarthrosis. The gomphosis is the only joint-type in which a bone does not join another bone, as teeth are not technically bone. In modern, more anatomical, joint classification, the gomphosis is simply considered a fibrous joint because the tissue linking the structures is ligamentous. It has been suggested that this permanent soft-tissue attachment was a critical requisite in the evolution of the mammalian (synapsid) tusk.
== Gene == The CTNS gene is located on the p arm of human chromosome 17, at position 13.2. It spans base pairs 3,636,468 and 3,661,542, and comprises 12 exons. In 1995, the gene was localized to the short arm of chromosome 17. An international collaborative effort finally succeeded in isolating CTNS by positional cloning in 1998. The CTNSN323K, CTNSK280R, and CTNSN288K mutations completely stop the movement of CySS out of the lysosome via cystinosin.[2] interestingly, CTNSN323K and CTNSK280R are related to juvenile nephropathic cystinosis while CTNSN288K mutations are found in cases with infantile nephropathic cystinosis.
== History == The drug was first discovered by scientists including Axel Ullrich and H. Michael Shepard at Genentech, Inc. in South San Francisco, CA. Earlier discovery about the neu oncogene by Robert Weinberg's lab and the monoclonal antibody recognizing the oncogenic receptor by Mark Greene's lab also contributed to the establishment of HER2 targeted therapies. Dr. Dennis Slamon subsequently worked on trastuzumab's development. A book about Dr. Slamon's work was made into a television film called Living Proof, that premiered in 2008. Genentech developed trastuzumab jointly with UCLA, beginning the first clinical trial with 15 women in 1992. By 1996, clinical trials had expanded to over 900 women, but due to pressure from advocates based on early success, Genentech worked with the FDA to begin a lottery system allowing 100 women each quarter access to the medication outside the trials. Herceptin was Fast-tracked by the FDA and gained approval in September 1998. Biocon Ltd and its partner Mylan obtained regulatory approval to sell a biosimilar in 2014, but Roche contested the legality of the approval; that litigation ended in 2016, and Biocon and Mylan each introduced their own branded biosimilars.
Sources: en.wikipedia.org
Honjōzō (本醸造; 'genuine fermented'): Contains 100% genuine fermented product Kongō-jōzō (混合醸造; 'mixed fermented'): Contains genuine fermented shōyu mash mixed with 30–50% of chemical or enzymatic hydrolysate of plant protein Kongō (混合; 'mixed'): Contains honjōzō or Kongō-jōzō shōyu mixed with 30–50% of chemical or enzymatic hydrolysate of plant protein All the varieties and grades may be sold according to three official levels of quality:
With 68.6 million tons of cargo in 2011, the port of Le Havre is the second largest French seaport in trade volume behind that of Marseille and 50th largest port in the world. It represents 60% of total French container traffic with nearly 2.2 million Twenty-foot equivalent unit|EVP]s in 2011. At the European level, it is eighth largest for container traffic and sixth largest for total traffic. The Port receives a large number of oil tankers that transported 27.5 million tonnes of crude oil and 11.7 million tonnes of refined product in 2011. Finally, 340,500 vehicles passed through the Roll-on/roll-off terminal in 2010. 75 regular shipping lines serve 500 ports around the world. The largest trading partner of the port of Le Havre is the Asian continent which alone accounts for 58% of imports by container and 39.6% of exports. The rest of the traffic is distributed mainly to Europe and America. Le Havre occupies the north bank of the estuary of the Seine on the Channel. Its location is favourable for several reasons: it is on the most frequented waterway in the world; it is the first and last port in the North Range of European ports – the largest in Europe which handles a quarter of all global maritime trade. As a deepwater port, it is accessible to all types of ships whatever their size around the clock. At the national level, Le Havre is 200 kilometres (124 mi) west of the most populous and richest region in France: Île-de-France.
Joshua Lederberg, “De’s clinical observations led him to the bold thought that dehydration was a sufficient cause of pathology of cholera, that the cholera toxin can kill ‘merely’ by stimulating the secretion of water into the bowel". Thus, the oral rehydration therapy (ORT) for replenishing the massive fluid loss in cholera patients, has saved innumerable lives, should be considered as a direct outcome of De's discovery of cholera toxin. His findings on exotoxins set the stage for the modern views of diseases caused by toxin producing bacteria, helped in the purification of cholera and heat-labile (LT) enterotoxins produced by V. cholerae and E. coli, respectively, and in the development of series of cholera and enterotoxigenic E. coli (in short ETEC strains) vaccines.
Tourism is a significant contributor to the Romanian economy, generating around 5% of GDP. The number of tourists has been rising steadily, reaching 9.33 million foreign tourists in 2016, according to the Worldbank. Tourism in Romania attracted €400 million in investments in 2005. More than 60% of the foreign visitors in 2007 were from other EU countries. The popular summer attractions of Mamaia and other Black Sea Resorts attracted 1.3 million tourists in 2009. Among Romania's spa towns and resorts are Buziaș, Băile Călacea, Moneasa, Băile Lipova, Călimănești, Amara, and Geoagiu-Băi. At the same time, seaside resorts such as Eforie, Mangalia, Saturn, Venus, Neptun, Olimp, and Mamaia (sometimes also called the Romanian Riviera) are among the main tourist attractions during the summer. Most popular skiing resorts are along the Valea Prahovei, Muntele Mic, Semenic, Straja and Poiana Brașov. Wine tourism is represented by areas such as Recaș, Silagiu, Odobești, Drăgășani, and Podgoria Aradului. Castles, fortifications, or strongholds as well as preserved medieval Transylvanian cities or towns such as Timișoara, Cluj-Napoca, Sibiu, Brașov, Alba Iulia, Baia Mare, Bistrița, Mediaș, Cisnădie, Sebeș, or Sighișoara also attract a large number of tourists. Bran Castle, near Brașov, is one of the most famous attractions in Romania, drawing hundreds of thousands of tourists every year as it is often (falsely) advertised as being Dracula's Castle. Other attractions include the Danube Delta or the Sculptural Ensemble of Constantin Brâncuși at Târgu Jiu.
=== Myomesin 2 === Myomesin 2 (also known as M-protein) is located in the M1 line of the M-band. It is encoded by the MYOM2 gene. There is currently only one known variant of myomesin 2 and it can be found in fast skeletal muscles and adult cardiac muscles. Myomesin 2 has been shown to have an inverse relationship with the expression of EH-myomesin; as cardiac muscles mature, EH-myomesin is downregulated while myomesin 2 is upregulated.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.